Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

Publisher： Karger

E-ISSN： 1423-0232|90|4|199-208

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.4, 2016-03, pp. : 199-208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population‐based cohort study

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1446-1455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: which patients with hepatitis B virus‐related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 908-910

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E240-E251

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 1, 2015-01 ,pp. : 46-54

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 90-96

John Wiley & Sons Inc

Access to resources Recommend Favorite